American Diabetes Association
Supplemental_Materials (1).pdf (4.1 MB)
Download file

Activation of disulfide redox switch in REDD1 promotes oxidative stress under hyperglycemic conditions

Download (4.1 MB)
posted on 2022-09-28, 20:41 authored by William P. Miller, Congzhou M. Sha, Siddharth Sunilkumar, Allyson L. Toro, Ashley M. VanCleave, Scot R. Kimball, Nikolay V. Dokholyan, Michael D. Dennis

The stress response protein regulated in development and DNA damage response 1 (REDD1) has been implicated in visual deficits in diabetic patients. The aim here was to investigate the mechanism responsible for the increase in retinal REDD1 protein content that is observed with diabetes. We found that REDD1 protein expression was increased in the retina of streptozotocin-induced diabetic mice in the absence of a change in REDD1 mRNA abundance or ribosome association. Oral antioxidant supplementation reduced retinal oxidative stress and suppressed REDD1 protein expression in the retina of diabetic mice. In human retinal Müller cell cultures, hyperglycemic conditions increased oxidative stress, enhanced REDD1 expression, and inhibited REDD1 degradation independently of the proteasome. Hyperglycemic conditions promoted a redox-sensitive cross-strand disulfide bond in REDD1 at C150/C157 that was required for reduced REDD1 degradation. Discrete molecular dynamics simulations of REDD1 structure revealed allosteric regulation of a degron upon formation of the disulfide bond that disrupted lysosomal proteolysis of REDD1. REDD1 acetylation at K129 was required for REDD1 recognition by the cytosolic chaperone HSC70 and degradation by chaperone-mediated autophagy. Disruption of REDD1 allostery upon C150/C157 disulfide bond formation prevented the suppressive effect of hyperglycemic conditions on REDD1 degradation and reduced oxidative stress in cells exposed to hyperglycemic conditions. The results reveal redox regulation of REDD1 and demonstrate the role of a REDD1 disulfide switch in development of oxidative stress.


This research was supported by American Diabetes Association Pathway to Stop Diabetes grant 1-14-INI-04, National Eye Institute grants R01 EY029702, R01 EY032879 (to MDD), and F31 EY031199 (to WPM). Support was also provided by the National Institute of General Medical Sciences (1R35 GM134864), the National Science Foundation (2040667), and the Passano Foundation (to NVD)